Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jules Leonard Dienstag, M.D.

Title
Institution
Department
Address
Phone
Other Positions
Title
Institution
Department

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. N01DK92319-17-0-1 (DIENSTAG, JULES L) May 1, 1999 - Apr 30, 2010
    NIH
    Hepatitis C Clinical Trial-Clinical Center
    Role: Principal Investigator
  2. N01DK092319 (DIENSTAG, JULES LEONARD) May 1, 1999 - Apr 30, 2007
    NIH/NIDDK
    HEPATITIS C CLINICAL TRIAL-CLINICAL CENTERS
    Role: Principal Investigator
  3. M01RR001066 (SLAVIN, PETER L) Feb 1, 1978 - May 31, 2008
    NIH
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Miloslavsky EM, Besche HC, Calderwood SB, Chang BS, Dienstag JL, King RW, Mitchell RN, Schwartzstein RM, Thomas H, Hundert EM, Flanagan JG. Advanced Integrated Science Courses: Building a Skill Set to Engage With the Interface of Research and Medicine. Acad Med. 2022 Feb 01. PMID: 35108233.
    Citations:    Fields:    
  2. Ghany MG, Lok ASF, Dienstag JL, Feinstone SM, Hoofnagle JH, Jake Liang T, Seeff LB, Cohen DE, Bezerra JA, Chung RT. The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. Hepatology. 2021 11; 74(5):2813-2823. PMID: 33784424.
    Citations:    Fields:    Translation:HumansCells
  3. Feldman TC, Dienstag JL, Mandl KD, Tseng YJ. Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C. Int J Med Inform. 2021 10; 154:104562. PMID: 34482150.
    Citations:    Fields:    Translation:Humans
  4. Dienstag JL. Introducing Raymond T. Chung, M.D., Our 2021 AASLD President. Hepatology. 2021 07; 74(1):12-18. PMID: 33759200.
    Citations:    Fields:    Translation:Humans
  5. Schwartzstein RM, Dienstag JL, King RW, Chang BS, Flanagan JG, Besche HC, Hoenig MP, Miloslavsky EM, Atkins KM, Puig A, Cockrill BA, Wittels KA, Dalrymple JL, Gooding H, Hirsh DA, Alexander EK, Fazio SB, Hundert EM. The Harvard Medical School Pathways Curriculum: Reimagining Developmentally Appropriate Medical Education for Contemporary Learners. Acad Med. 2020 11; 95(11):1687-1695. PMID: 32134787.
    Citations: 3     Fields:    Translation:Humans
  6. Krupat E, Dienstag JL, Padrino SL, Mayer JE, Shore MF, Young A, Chaudhry HJ, Pelletier SR, Reis BY. Do Professionalism Lapses in Medical School Predict Problems in Residency and Clinical Practice? Acad Med. 2020 06; 95(6):888-895. PMID: 31895703.
    Citations: 5     Fields:    Translation:Humans
  7. Luther J, Khan S, Gala MK, Kedrin D, Sridharan G, Goodman RP, Garber JJ, Masia R, Diagacomo E, Adams D, King KR, Piaker S, Reinecker HC, Yarmush ML, Argemi J, Bataller R, Dienstag JL, Chung RT, Patel SJ. Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. Proc Natl Acad Sci U S A. 2020 05 26; 117(21):11667-11673. PMID: 32393626.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  8. Dienstag JL. Kurt J. Isselbacher, M.D., Remembered (1925-2019). Hepatology. 2020 Mar; 71(3):1135-1139. PMID: 31970804.
    Citations:    Fields:    
  9. Krupat E, Camargo CA, Espinola JA, Fleenor TJ, Strewler GJ, Dienstag JL. A snapshot of underrepresented physicians 15 years after medical school. Adv Health Sci Educ Theory Pract. 2020 08; 25(3):711-730. PMID: 31982974.
    Citations:    Fields:    Translation:Humans
  10. Bloom PP, Mojtahed A, Bethea ED, Knooihuizen SA, Choi J, Dienstag JL, Chung RT, Hur C. Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes. Dig Dis Sci. 2020 01; 65(1):312-321. PMID: 31363954.
    Citations:    Fields:    Translation:Humans
  11. Ufere NN, Donlan J, Waldman L, Patel A, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer J, Temel J, Chung RT, El-Jawahri A. Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study. Liver Transpl. 2019 06; 25(6):859-869. PMID: 30963669.
    Citations: 8     Fields:    Translation:Humans
  12. Ufere NN, Donlan J, Waldman L, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer JA, Temel JS, Chung RT, El-Jawahri A. Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease. Clin Gastroenterol Hepatol. 2019 11; 17(12):2592-2599. PMID: 30885884.
    Citations: 15     Fields:    Translation:Humans
  13. Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018 10 01; 29(10):2085-2091. PMID: 30165371.
    Citations: 71     Fields:    Translation:Humans
  14. Luther J, Dienstag JL. Reply to: "Primed for the spotlight: Transplantation for alcohol-associated liver disease". J Hepatol. 2018 07; 69(1):255. PMID: 29650334.
    Citations:    Fields:    Translation:Humans
  15. Luther J, Dienstag JL. Hardened Liver Due to Fibrolamellar Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2019 01; 17(1):A27. PMID: 29505903.
    Citations:    Fields:    Translation:Humans
  16. Luther J, Dienstag JL. Reply to: "Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach". J Hepatol. 2018 06; 68(6):1323. PMID: 29505846.
    Citations:    Fields:    Translation:Humans
  17. Kubiliun M, Patel SJ, Hur C, Dienstag JL, Luther J. Early liver transplantation for alcoholic hepatitis: Ready for primetime? J Hepatol. 2018 03; 68(3):380-382. PMID: 29175244.
    Citations: 2     Fields:    Translation:Humans
  18. Allegretti AS, Parada XV, Eneanya ND, Gilligan H, Xu D, Zhao S, Dienstag JL, Chung RT, Thadhani RI. Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. Clin J Am Soc Nephrol. 2018 01 06; 13(1):16-25. PMID: 29122911.
    Citations: 15     Fields:    Translation:Humans
  19. Krupat E, Pelletier SR, Dienstag JL. Academic Performance on First-Year Medical School Exams: How Well Does It Predict Later Performance on Knowledge-Based and Clinical Assessments? Teach Learn Med. 2017 Apr-Jun; 29(2):181-187. PMID: 28098483.
    Citations: 2     Fields:    Translation:Humans
  20. Krupat E, Camargo CA, Strewler GJ, Espinola JA, Fleenor TJ, Dienstag JL. Factors associated with physicians' choice of a career in research: a retrospective report 15 years after medical school graduation. Adv Health Sci Educ Theory Pract. 2017 Mar; 22(1):5-15. PMID: 27112959.
    Citations: 7     Fields:    Translation:Humans
  21. Krupat E, Dienstag JL, Kester WC, Finkelstein SN. Medical Students Who Pursue a Joint MD/MBA Degree: Who Are They and Where Are They Heading? Eval Health Prof. 2017 06; 40(2):203-218. PMID: 26801747.
    Citations: 4     Fields:    Translation:Humans
  22. Snow KK, Bell MC, Stoddard AM, Curto TM, Wright EC, Dienstag JL. Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials. 2014 May 07; 15:159. PMID: 24886378.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  23. Leape L, Shore M, Dienstag JL. In reply to Alexander et al. Acad Med. 2013 Jun; 88(6):741-2. PMID: 23708592.
    Citations:    Fields:    Translation:Humans
  24. Dienstag JL, Cosimi AB. Liver transplantation--a vision realized. N Engl J Med. 2012 Oct 18; 367(16):1483-5. PMID: 22992048.
    Citations: 20     Fields:    Translation:Humans
  25. Dienstag JL. The case for the new MCAT. N Engl J Med. 2012 07 19; 367(3):280-1; author reply 281-2. PMID: 22808979.
    Citations:    Fields:    Translation:Humans
  26. Leape LL, Shore MF, Dienstag JL, Mayer RJ, Edgman-Levitan S, Meyer GS, Healy GB. Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians. Acad Med. 2012 Jul; 87(7):845-52. PMID: 22622217.
    Citations: 68     Fields:    Translation:Humans
  27. Leape LL, Shore MF, Dienstag JL, Mayer RJ, Edgman-Levitan S, Meyer GS, Healy GB. Perspective: a culture of respect, part 2: creating a culture of respect. Acad Med. 2012 Jul; 87(7):853-8. PMID: 22622219.
    Citations: 44     Fields:    Translation:Humans
  28. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol. 2012 Sep; 107(9):1388-98. PMID: 22688849.
    Citations: 7     Fields:    Translation:Humans
  29. Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One. 2012; 7(2):e27144. PMID: 22359532.
    Citations: 17     Fields:    Translation:Humans
  30. Dienstag JL. The Medical College Admission Test--toward a new balance. N Engl J Med. 2011 Nov 24; 365(21):1955-7. PMID: 22111717.
    Citations: 4     Fields:    
  31. Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int. 2012 Apr; 32(4):665-74. PMID: 22103814.
    Citations: 8     Fields:    Translation:HumansCells
  32. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012 Jan; 107(1):64-74. PMID: 21931376.
    Citations: 43     Fields:    Translation:Humans
  33. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54(2):396-405. PMID: 21520194.
    Citations: 52     Fields:    Translation:Humans
  34. Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology. 2011 Sep; 141(3):900-908.e1-2. PMID: 21699796.
    Citations: 14     Fields:    Translation:Humans
  35. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8. PMID: 21480316.
    Citations: 14     Fields:    Translation:Humans
  36. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul; 141(1):141-9. PMID: 21440548.
    Citations: 67     Fields:    Translation:Humans
  37. Dienstag JL. Evolution of the New Pathway curriculum at Harvard Medical School: the new integrated curriculum. Perspect Biol Med. 2011; 54(1):36-54. PMID: 21399382.
    Citations: 10     Fields:    Translation:Humans
  38. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Dig Dis Sci. 2011 Feb; 56(2):564-8. PMID: 21136163.
    Citations: 31     Fields:    Translation:Humans
  39. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar; 140(3):840-9; quiz e12. PMID: 21129375.
    Citations: 86     Fields:    Translation:HumansCells
  40. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep; 52(3):833-44. PMID: 20564351.
    Citations: 147     Fields:    Translation:Humans
  41. Dienstag JL, Neill JM. Harvard Medical School. Acad Med. 2010 Sep; 85(9 Suppl):S269-73. PMID: 20736566.
    Citations:    Fields:    
  42. Dienstag JL. Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eye. Am J Gastroenterol. 2010 Aug; 105(8):1770-2. PMID: 20686463.
    Citations: 1     Fields:    Translation:Humans
  43. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010 Oct; 59(10):1401-9. PMID: 20675691.
    Citations: 34     Fields:    Translation:Humans
  44. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010 Oct; 8(10):877-83. PMID: 20362695.
    Citations: 116     Fields:    Translation:HumansCTClinical Trials
  45. Peters MG, Weinbaum C, Tan L, Baine WB, Dienstag JL, Liang TJ, So S. Recommendations for prevention, screening, and diagnosis of HBV and HCV infections. J Fam Pract. 2010 Apr; 59(4 Suppl):S29-35. PMID: 20398588.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  46. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010 Feb; 51(2):585-94. PMID: 20101752.
    Citations: 45     Fields:    Translation:Humans
  47. Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010 Apr; 31(7):719-34. PMID: 20070284.
    Citations: 8     Fields:    Translation:Humans
  48. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology. 2009 Dec; 50(6):1738-49. PMID: 19824074.
    Citations: 26     Fields:    Translation:Humans
  49. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009 Nov; 50(5):1360-9. PMID: 19676128.
    Citations: 39     Fields:    Translation:Humans
  50. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010 Feb; 138(2):493-502. PMID: 19852963.
    Citations: 206     Fields:    Translation:Humans
  51. Bardes CL, Best PC, Kremer SJ, Dienstag JL. Perspective: Medical school admissions and noncognitive testing: some open questions. Acad Med. 2009 Oct; 84(10):1360-3. PMID: 19881422.
    Citations: 3     Fields:    Translation:Humans
  52. Corey KE, Servoss JC, Casson DR, Kim AY, Robbins GK, Franzini J, Twitchell K, Loomis SC, Abraczinskas DR, Terella AM, Dienstag JL, Chung RT. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect Control Hosp Epidemiol. 2009 Oct; 30(10):1000-5. PMID: 19743901.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  53. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology. 2010 Jan; 138(1):136-46. PMID: 19766643.
    Citations: 33     Fields:    Translation:Humans
  54. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009 Dec; 137(6):1986-94. PMID: 19747918.
    Citations: 10     Fields:    Translation:HumansCells
  55. Krupat E, Dienstag JL. Commentary: Assessment is an educational tool. Acad Med. 2009 May; 84(5):548-50. PMID: 19704183.
    Citations: 8     Fields:    Translation:Humans
  56. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009 May; 49(5 Suppl):S112-21. PMID: 19399795.
    Citations: 50     Fields:    Translation:HumansCells
  57. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 04; 359(23):2429-41. PMID: 19052125.
    Citations: 146     Fields:    Translation:HumansCells
  58. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):219-26. PMID: 19068241.
    Citations: 19     Fields:    Translation:Humans
  59. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology. 2008 Nov; 48(5):1412-9. PMID: 18816437.
    Citations: 8     Fields:    Translation:HumansCells
  60. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008 Oct 02; 359(14):1486-500. PMID: 18832247.
    Citations: 305     Fields:    Translation:HumansCells
  61. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009 Jan; 136(1):138-48. PMID: 18848939.
    Citations: 204     Fields:    Translation:Humans
  62. Dienstag JL. Relevance and rigor in premedical education. N Engl J Med. 2008 Jul 17; 359(3):221-4. PMID: 18635426.
    Citations: 11     Fields:    
  63. Dienstag JL. Hepatitis A: the vaccine dividend. J Infect Dis. 2008 May 01; 197(9):1220-2. PMID: 18422432.
    Citations:    Fields:    Translation:HumansCells
  64. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008 Mar; 47(3):789-98. PMID: 18175357.
    Citations: 52     Fields:    Translation:Humans
  65. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol. 2008 Feb; 6(2):234-41. PMID: 18237873.
    Citations: 11     Fields:    Translation:HumansCells
  66. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008 Feb; 47(2):605-12. PMID: 18157835.
    Citations: 56     Fields:    Translation:Humans
  67. Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. 2008 Feb; 15(2):129-36. PMID: 18184196.
    Citations: 13     Fields:    Translation:Cells
  68. Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis. 2007 Nov; 11(4):851-68, ix. PMID: 17981232.
    Citations: 5     Fields:    Translation:HumansCells
  69. Dienstag J, Easley C, Kirkpatrick P. Telbivudine. Nat Rev Drug Discov. 2007 Apr; 6(4):267-8. PMID: 17458000.
    Citations: 9     Fields:    Translation:HumansCells
  70. Dienstag JL, Wei LJ, Xu D, Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig. 2007; 27(1):35-49. PMID: 17177578.
    Citations: 8     Fields:    Translation:Humans
  71. Bourne EJ, Dienstag JL, Lopez VA, Sander TJ, Longlet JM, Hall JG, Kwiatkowski RW, Wright T, Lai CL, Condreay LD. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat. 2007 Jan; 14(1):55-63. PMID: 17212645.
    Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
  72. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006 Dec; 44(6):1675-84. PMID: 17133499.
    Citations: 40     Fields:    Translation:Humans
  73. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007 Mar; 46(3):420-31. PMID: 17196293.
    Citations: 46     Fields:    Translation:Humans
  74. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007 Jan; 132(1):103-12. PMID: 17241864.
    Citations: 57     Fields:    Translation:HumansCells
  75. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology. 2006 Aug; 44(2):360-7. PMID: 16871570.
    Citations: 14     Fields:    Translation:HumansCells
  76. Dienstag JL. Hepatitis C: a bitter harvest. Ann Intern Med. 2006 May 16; 144(10):770-1. PMID: 16702593.
    Citations: 5     Fields:    Translation:Humans
  77. Dienstag JL. Looking to the future: new agents for chronic hepatitis B. Am J Gastroenterol. 2006; 101 Suppl 1:S19-25. PMID: 16448448.
    Citations: 1     Fields:    Translation:HumansCells
  78. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006 Jan; 130(1):231-64; quiz 214-7. PMID: 16401486.
    Citations: 92     Fields:    Translation:HumansPHPublic Health
  79. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. 2006 Jan; 130(1):225-30. PMID: 16401485.
    Citations: 38     Fields:    Translation:Humans
  80. Wright TL, Avunduk C, Dienstag JL, Freston JW, Jacobson IM, Nord HJ, Sherman M. Advancing patient care: integrating new data. Am J Gastroenterol. 2006; 101 Suppl 1:S32-9. PMID: 16448450.
    Citations: 1     Fields:    Translation:Humans
  81. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005 Sep; 43(3):434-41. PMID: 16136646.
    Citations: 124     Fields:    Translation:HumansCTClinical Trials
  82. Di Giammarino L, Dienstag JL. Hepatitis A--the price of progress. N Engl J Med. 2005 Sep 01; 353(9):944-6. PMID: 16135841.
    Citations: 6     Fields:    Translation:HumansAnimalsPHPublic Health
  83. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005 Aug; 42(2):282-92. PMID: 15986415.
    Citations: 91     Fields:    Translation:Humans
  84. Dienstag JL. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B. J Hepatol. 2005 Feb; 42(2):158-62. PMID: 15664237.
    Citations: 1     Fields:    Translation:Humans
  85. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004 Oct; 25(5):472-92. PMID: 15465617.
    Citations: 68     Fields:    Translation:HumansCTClinical Trials
  86. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004 Apr; 126(4):1015-23; discussion 947. PMID: 15057741.
    Citations: 103     Fields:    Translation:HumansCTClinical Trials
  87. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol. 2004 Mar; 2(3):266-72. PMID: 15017612.
    Citations: 23     Fields:    Translation:Humans
  88. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003 Dec; 125(6):1714-22. PMID: 14724824.
    Citations: 206     Fields:    Translation:HumansCellsCTClinical Trials
  89. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, de Man RA, Goodman Z, Condreay LD, Crowther LM, Woessner MA, McPhillips PJ, Brown NA. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003 Jun; 38(6):818-26. PMID: 12763376.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  90. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003 Apr; 37(4):748-55. PMID: 12668966.
    Citations: 44     Fields:    Translation:HumansCellsCTClinical Trials
  91. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003 Mar 15; 36(6):687-96. PMID: 12627352.
    Citations: 164     Fields:    Translation:HumansCellsCTClinical Trials
  92. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003 Jan; 124(1):105-17. PMID: 12512035.
    Citations: 178     Fields:    Translation:HumansCellsCTClinical Trials
  93. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002 Nov; 36(5 Suppl 1):S152-60. PMID: 12407589.
    Citations: 73     Fields:    Translation:Humans
  94. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002 Oct; 123(4):1061-9. PMID: 12360468.
    Citations: 218     Fields:    Translation:HumansCells
  95. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002 Jul; 36(1):186-94. PMID: 12085364.
    Citations: 60     Fields:    Translation:HumansCellsCTClinical Trials
  96. McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling MH, Garaud JJ, Albrecht JK, Patel K, Dienstag JL, Morgan T. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology. 2002 Mar; 35(3):688-93. PMID: 11870385.
    Citations: 29     Fields:    Translation:Humans
  97. Rosenberg PM, Farrell JJ, Abraczinskas DR, Graeme-Cook FM, Dienstag JL, Chung RT. Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfection. Am J Gastroenterol. 2002 Feb; 97(2):478-83. PMID: 11866292.
    Citations: 14     Fields:    Translation:Humans
  98. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, Schoonhoven R, Brenner DA, Fried MW, Burkhardt E. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001 Dec; 35(6):749-55. PMID: 11738102.
    Citations: 49     Fields:    Translation:HumansCTClinical Trials